| dc.contributor.author | Mahesh, R. | |
| dc.date.accessioned | 2023-11-22T10:56:57Z | |
| dc.date.available | 2023-11-22T10:56:57Z | |
| dc.date.issued | 2016 | |
| dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345311/ | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13224 | |
| dc.description.abstract | Alteration in the serotonin leads to the psychological illness, such as depression, anxiety, schizophrenia, eating disorders, obsessive-compulsive disorder, panic disorders and migraines. The objective of the current study was to investigate the antidepressant and anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide (QCF-21), a novel 5-HT3 receptor antagonist in preclinical models of depression and anxiety. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | IJMR | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Anxiety | en_US |
| dc.subject | Behavioural tests | en_US |
| dc.subject | Depression | en_US |
| dc.subject | N-(pyridin-3-yl) quinoxalin-2-carboxamide | en_US |
| dc.subject | Novel 5-HT3 antagonist | en_US |
| dc.subject | Serotonin system | en_US |
| dc.title | Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||